Non-Current Assets
AFS Securities
Neurocrine Biosciences AFS Securities increased by 25.2% to $1.33B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 63.3%, from $815.30M to $1.33B. Over 5 years (FY 2020 to FY 2025), AFS Securities shows an upward trend with a 36.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2017
Last reportedQ1 2026May 5, 2026
Parent metricTotal investment securities
How to read this metric
An increase reflects capital allocation toward investment portfolios, while a decrease may signal portfolio rebalancing or asset liquidation.
Detailed definition
Available-for-sale securities are debt or equity investments that are not classified as trading or held-to-maturity, and...
Peer comparison
Common in the investment portfolios of banks and insurance companies.
Metric ID:
fin_afs_securitiesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $337.80M | $513.70M | $560.70M | $541.00M | $405.20M | $362.60M | $299.40M | $244.60M | $342.60M | $454.70M | $687.50M | $700.40M | $637.80M | $643.90M | $739.50M | $815.30M | $873.80M | $998.50M | $1.06B | $1.33B |
| QoQ Change | — | +52.1% | +9.1% | -3.5% | -25.1% | -10.5% | -17.4% | -18.3% | +40.1% | +32.7% | +51.2% | +1.9% | -8.9% | +1.0% | +14.8% | +10.3% | +7.2% | +14.3% | +6.5% | +25.2% |
| YoY Change | — | — | — | — | +20.0% | -29.4% | -46.6% | -54.8% | -15.4% | +25.4% | +129.6% | +186.3% | +86.2% | +41.6% | +7.6% | +16.4% | +37.0% | +55.1% | +43.7% | +63.3% |
Range$244.60M – $1.33B
CAGR+33.5%
Avg YoY Growth+35.4%
Median YoY Growth+31.2%
Current Streak7 quarters growth
AFS Securities at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's afs securities?
- Neurocrine Biosciences (NBIX) reported afs securities of $1.33B in Q1 2026.
- How has Neurocrine Biosciences's afs securities changed year-over-year?
- Neurocrine Biosciences's afs securities increased by 63.3% year-over-year, from $815.30M to $1.33B.
- What is the long-term trend for Neurocrine Biosciences's afs securities?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's afs securities has grown at a 36.2% compound annual growth rate (CAGR), from $227.10M to $1.06B.
- What does afs securities mean?
- Investments in securities that are held for potential sale and marked to fair market value.